USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1

Tumour suppressor p53 levels in the cell are tightly regulated by controlled degradation through ubiquitin ligases including Mdm2, COP1, Pirh2, and ARF‐BP1. The ubiquitination process is reversible via deubiquitinating enzymes, such as ubiquitin‐specific peptidases (USPs). In this study, we identifi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The EMBO journal 2011-06, Vol.30 (11), p.2177-2189
Hauptverfasser: Zhang, Xinna, Berger, Franklin G, Yang, Jianhua, Lu, Xiongbin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tumour suppressor p53 levels in the cell are tightly regulated by controlled degradation through ubiquitin ligases including Mdm2, COP1, Pirh2, and ARF‐BP1. The ubiquitination process is reversible via deubiquitinating enzymes, such as ubiquitin‐specific peptidases (USPs). In this study, we identified ubiquitin‐specific peptidase 4 (USP4) as an important regulator of p53. USP4 interacts directly with and deubiquitinates ARF‐BP1, leading to the stabilization of ARF‐BP1 and subsequent reduction of p53 levels. Usp4 knockout mice are viable and developmentally normal, but showed enhanced apoptosis in thymus and spleen in response to ionizing radiation. Compared with wild‐type mouse embryonic fibroblasts (MEFs), Usp4 −/− MEFs exhibited retarded growth, premature cellular senescence, resistance to oncogenic transformation, and hyperactive DNA damage checkpoints, consistent with upregulated levels and activity of p53 in the absence of USP4. Finally, we showed that USP4 is overexpressed in several types of human cancer, suggesting that USP4 is a potential oncogene. Another DUB joins the ranks of deubiquitinating enzymes involved in p53 regulation. USP4 acts on the ubiquitin ligase ARF‐BP1/Mule/Huwe1, thus decreasing p53 levels and responses; while senescence ensues in USP4‐deficient cells.
ISSN:0261-4189
1460-2075
DOI:10.1038/emboj.2011.125